Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like Ignyta To Present At 2016 Healthcare Conference July 8, 2016 Ceapro Reports 2016 Financial Results And Provides Corporate Update April 5, 2017 Pfizer Wins Expanded FDA Nod for Cancer Drug Sutent November 16, 2017
